You are here: Industry Insights > GlobalData

News List

Low asthma patient adherence shows need for personalised and convenient medicines: GlobalData expresspharma
April 14, 2021
GlobalData has revealed that 80 per cent of asthma patients do not take their medication effectively. The reasons for this poor patient adherence are numerous and can include poor inhaler technique, poor perception, complex regimens and the cost of ...
US, India lead in COVID-19 clinical trials benefitted by large patient pools: GlobalData expresspharma
April 09, 2021
The US is running the highest number of COVID-19 clinical trials in the world, according to the clinical trial database by GlobalData. As of early March, the country saw 823 trials. This was followed by India at 491.
Novel pipeline agents to drive global major depressive disorder market: GlobalData expresspharma
April 08, 2021
The major depressive disorder (MDD) market is expected to grow from $3.97 billion in 2019 to $7.87 billion by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.1 per cent, according to GlobalData.
Resumed clinical trials will grow gradually with COVID-19 vaccine rollout: GlobalData expresspharma
March 31, 2021
With the expected decrease in monthly COVID-19 cases due to increasing vaccinations in countries such as the US and the UK, GlobalData expects clinical trials to resume more quickly in these countries.
300 per cent increase in companies conducting endometriosis clinical trials since 2010: GlobalData expresspharma
March 30, 2021
Bayer, Ferring International and AbbVie were among the most highly active sponsors with 21, 11 and seven trials, respectively.
Chemotherapy uptake to gradually decrease with arrival of novel therapies and biosimilars- GlobalData expresspharma
March 26, 2021
Trends in chemotherapy sales are expected to vary widely with CAGRs ranging from -14.92 per cent to 8.40 per cent across 15 major.
92 per cent decrease in UK COVID-19 cases since Jan: GlobalData expresspharma
March 22, 2021
The ending of the national lockdown and the reopening of schools and non-essential industries in April will be a true test of the effectiveness of the vaccinations in limiting the spread of the virus.
Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData expresspharma
March 16, 2021
The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets was identified to be measures of tumour mutational burden.
China continues to lead high value oncology deals in APAC: GlobalData expresspharma
March 15, 2021
High-value deals have dominated the Asia-Pacific (APAC) pharma strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly in the field of oncology, reveals GlobalData.
Low patient accrual rates cause termination of over 25 per cent rare disease trials: GlobalData expresspharma
March 11, 2021
Difficulties with patient recruitment for rare disease clinical trials could be mitigated by the use of virtual trials.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page